GLORIA

GEOMAR Library Ocean Research Information Access

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Erythropoietin uraemia  (1)
  • Hydroxyurea  (1)
  • Springer  (2)
  • 1
    ISSN: 1432-0584
    Keywords: CML ; Busulfan ; Hydroxyurea ; Interferon-alpha ; Duration of chronic phase ; Prospective study
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 51 (1973), S. 1005-1009 
    ISSN: 1432-1440
    Keywords: Erythropoietin uraemia ; Erythropoetin ; Niereninsuffizienz
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung 400 ml Erythropoetin-reiches Plasma (entsprechend 500 E Erythropoetin) von Patienten, die an aplastischer Anämie litten, wurden drei männlichen Normalpersonen infundiert. Die Normalpersonen reagierten mit einem Anstieg der absoluten Reticulocytenzahl von 60–100%. Das Maximum der Reticulocytenkrise wurde 36 Std nach der Erythropoetingabe beobachtet. Dieser Befund spricht dafür, daß Erythropoetin die Erythropoese nicht nur durch Stimulation von Stammzellen steigert. Bei zwei nicht dialysierten Patienten mit Niereninsuffizienz und bei zwei Patienten des chronischen Hämodialyseprogramms erfolgte nach Infusion von 500 E Erythropoetin kein signifikanter Anstieg der Reticulocyten. Bei einem weiteren Patienten des chronischen Hämodialyseprogramms erfolgte nach Infusion von zweimal je 935 E Erythropoetin eine Reticulocytenkrise. Die Ergebnisse zeigen, daß bei urämischer Intoxikation eine relative Unempfindlichkeit des Knochenmarkes gegenüber Erythropoetin besteht.
    Notes: Summary Fourhundred ml of erythropoietin-rich plasma (the equivalent of 500 µ of erythropoietin) obtained from patients suffering from aplastic anaemia were infused to three normal males. In the normal subjects reticulocytes increased from 60 to 100%, with the maximum response being observed at 36 hours. These results suggest that erythropoietin does not act upon the stem cells alone. After infusion of 500 µ of erythropoietin into two nondialysed uraemic patients and two chronic intermittent hemodialysed patients, there was no significant increase in reticulocytes. However, one patient on chronic intermittent hemodialysis who twice received 935 µ of erythropoietin showed a marked increased in reticulocytes. It is concluded that there is a relative insensitivity of bone marrow to erythropoietin in chronic uraemia.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...